Search Results

You are looking at 31 - 40 of 51 items for :

  • "myeloid growth factors" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H. Page, and Chun Chao

(CRC); bendamustine with or without rituximab (B±R) for non-Hodgkin's lymphoma (NHL); and lenalidomide with or without dexamethasone for multiple myeloma (MM). When this study was initiated, TC was established by the NCCN Myeloid Growth Factors

Full access

Neelima Denduluri, Debra A. Patt, Yunfei Wang, Menaka Bhor, Xiaoyan Li, Anne M. Favret, Phuong Khanh Morrow, Richard L. Barron, Lina Asmar, Shanmugapriya Saravanan, Yanli Li, Jacob Garcia, and Gary H. Lyman

-stimulating factor (CSF) prophylaxis in cycle 1 was consistently high for the 3 breast cancer regimens with a high risk (>20%) of FN according to the NCCN Guidelines for Myeloid Growth Factors 29 (from 89.1% for dose-dense AC followed by paclitaxel every 2 weeks to

Full access

Lymphocytic Leukemia/Small Lymphocytic Lymphoma Colon Cancer Esophageal Cancer Gastric Cancer Gestational Trophoblastic Neoplasia (GTN) Head and Neck Cancers (concentrating on the lip, oral, and oropharynx) Kaposi Sarcoma Kidney Cancer Myeloid Growth Factors

Full access

Jeremy Lund, Angela Pearson, and Georgia Keriazes

during the first cycle of cancer chemotherapy, when patients are treated with full-dose chemotherapy without supportive care.” However, the use of primary prophylaxis with a myeloid growth factor was not evaluated in our study and is considered to be a

Full access

Andrew D. Zelenetz, Islah Ahmed, Edward Louis Braud, James D. Cross, Nancy Davenport-Ennis, Barry D. Dickinson, Steven E. Goldberg, Scott Gottlieb, Philip E. Johnson, Gary H. Lyman, Richard Markus, Ursula A. Matulonis, Denise Reinke, Edward C. Li, Jessica DeMartino, Jonathan K. Larsen, and James M. Hoffman

), myeloid growth factors, and somatropins are currently available in the European market. 2 , 6 The EMA is expected to finalize its guideline on requirements for biosimilar products containing monoclonal antibodies in 2011. 7 The EMA also allows for

Full access

V.1.2014; Acute Myeloid Leukemia V.2.2014; Bladder Cancer V.2.2014; Chronic Myelogenous Leukemia V.3.2014; Hodgkin Lymphoma (V.2.2013); Multiple Myeloma (V.2.2014); Myeloid Growth Factors (V.2.2013); Systemic Light Chain Amyloidosis (V.2

Full access

Archie Bleyer

, are the published guidelines on cancer pain, antiemesis, cancer- and chemotherapy-induced anemia, cancer-related fatigue, distress management, myeloid growth factors, palliative care, prevention and treatment of cancer-related infections, or venous

Full access

Leila Family, Yanli Li, Lie Hong Chen, John H. Page, Zandra K. Klippel, and Chun Chao

Jansson JK . Long-term impacts of antibiotic exposure on the human intestinal microbiota . Microbiology 2010 ; 156 : 3216 – 3223 . 24. Crawford J Armitage J Balducci L . Myeloid growth factors . J Natl Compr Canc Netw 2009 ; 7 : 64 – 83

Full access

Pamela S. Becker

benefit most from plerixafor, or who may even use the agent in a rescue strategy, can now be predicted, thus optimizing the cost-effectiveness. The role of biosimilar myeloid growth factors in mobilization has yet to be defined. Novel growth factors and

Full access

Rowena N. Schwartz, Kirby J. Eng, Deborah A. Frieze, Tracy K. Gosselin, Niesha Griffith, Amy Hatfield Seung, Jennifer M. Hinkel, Philip E. Johnson, Shirley A. Johnson, Edward C. Li, Audrea Hotsko Szabatura, and Michael K. Wong

agents, myeloid growth factors), oral anticancer agents, and, in some instances, parenteral chemotherapy or biologic agents. The proposed goals of specialty pharmacy include the optimization of pharmaceutical care outcomes through ensuring appropriate